Related Experiment Video
Updated: Jun 13, 2026
09:02
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
Chronic Lymphocytic Leukemia: Molecular Pathologies and Therapeutic Strategies
Kelly Meza1, Carla Barrientos Risso2, Ankit Shah3,4
1Department of Internal Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
International Journal of Molecular Sciences
|June 12, 2026
Summary
Targeted therapies like Bruton tyrosine kinase inhibitors and BCL2 inhibitors have transformed chronic lymphocytic leukemia (CLL) treatment. This review covers modern strategies, including risk stratification and measurable residual disease-guided approaches.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Chronic lymphocytic leukemia (CLL) therapy has significantly advanced.
- Targeted agents, including Bruton tyrosine kinase inhibitors (BTKis) and BCL2 inhibitors (BCL2is), are now central to treatment paradigms.
Purpose of the Study:
- To review current frontline and relapsed/refractory treatment strategies for CLL.
- To highlight the role of molecular risk stratification, combination therapies, and measurable residual disease (MRD)-guided treatment.
- To examine factors influencing CLL progression and treatment outcomes.
Main Methods:
- Literature review of contemporary CLL treatment strategies.
- Analysis of data regarding molecular risk stratification.
- Examination of combination and triplet regimens.
- Evaluation of MRD-guided therapy and time-limited approaches.
- Assessment of influencing factors like genomic complexity and prior therapies.
Main Results:
- Targeted agents (BTKis, BCL2is) represent a major shift in CLL management.
- Molecular risk stratification is crucial for tailoring treatment.
- Combination and triplet regimens show promise in improving outcomes.
- MRD monitoring guides treatment decisions and duration.
- Genomic complexity and patient factors impact treatment effectiveness.
Conclusions:
- Contemporary CLL treatment emphasizes personalized approaches based on molecular profiling and MRD status.
- Time-limited, targeted therapies offer new hope for patients.
- Further research is needed to optimize treatment sequencing and management of resistance.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...